Surely it is the other way round. The NHS could up its intake of new medicines willy-nilly, knowing that the industry would have to pay a rebate to the department. In essence, industry would be paying for the uptake of new medicines. The problem is that the Treasury discounts the figure. It makes an estimate of what the rebate is likely to be in the next financial year and builds it into the baseline budget, which is based on minimal growth.
Health Service Medical Supplies (Costs) Bill
Proceeding contribution from
Lord Hunt of Kings Heath
(Labour)
in the House of Lords on Monday, 23 January 2017.
It occurred during Debate on bills
and
Committee proceeding on Health Service Medical Supplies (Costs) Bill.
About this proceeding contribution
Reference
778 c52GC Session
2016-17Chamber / Committee
House of Lords Grand CommitteeSubjects
Librarians' tools
Timestamp
2021-10-12 15:12:04 +0100
URI
http://hansard.intranet.data.parliament.uk/Lords/2017-01-23/1701242000099
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Lords/2017-01-23/1701242000099
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Lords/2017-01-23/1701242000099